Approved October 2011
transfusional iron overload due to thalassemia
Ferriprox (deferiprone) is a chelating agent with an affinity for ferric ion (iron III). Deferiprone binds with ferric ions to form neutral complexes that are stable over a wide range of pH values.
Ferriprox is specifically indicated for patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
Ferriprox is supplied as a tablet for oral administration. The recommended initial dose is 25 mg/kg, orally, three times per day for a total of 75 mg/kg/day. The maximum dose is 33 mg/kg, three times per day for a total of 99 mg/kg/day.
The FDA approval of Ferriprox was based on 12 clinical studies in 236 subjects who did not respond to prior iron chelation therapy. Ferriprox therapy (35-99 mg/kg/day) was considered successful in individuals who experienced a greater than or equal to 20% decline in serum ferritin within one year of starting therapy. Of the 236 enrolled subjects, 50% reached the endpoint of at least a 20% reduction in serum ferritin.
Adverse events associated with the use of Ferriprox may include, but are not limited to, the following:
Ferriprox is a chelating agent with an affinity for ferric ion (iron III). Deferiprone binds with ferric ions to form neutral complexes that are stable over a wide range of pH values.
For additional information regarding Ferriprox or transfusional iron overload due to thalassemia, please visit the Ferriprox web page.
The Ferriprox drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.